A recent survey asked patients with primary and recurrent ovarian cancer to consider their reasons for choosing maintenance therapy following surgery and chemotherapy. READ MORE

Conferences

British liquid biopsy company Angle said its Parsortix blood test had beaten current methods in identifying ovarian cancer, a breakthough that could help women receive the best possible outcome from surgery.

READ MORE

Researchers compared intensity-modulated radiation therapy versus conventional radiation therapy by evaluating acute toxicities in the GI and GU systems.

READ MORE

Prolonging platinum-free interval by introducing non-platinum-based chemotherapy may actually worsen efficacy outcomes in patients with recurrent ovarian cancer.

READ MORE

News

A recent survey asked patients with primary and recurrent ovarian cancer to consider their reasons for choosing maintenance therapy following surgery and chemotherapy.

READ MORE

A recent study assessed whether neoadjuvant chemotherapy is superior to primary debulking surgery with regard to mortality and quality of life for patients with advanced epithelial ovarian cancer.

READ MORE

A recent study found that treatment with PARP inhibitors significantly increases the risk of hematologic toxicities and warrants frequent clinical monitoring by clinicians.

READ MORE

ICER confirmed in a recent report that evidence is lacking for outcomes comparisons of PARP inhibitors to treat ovarian cancer, and that prices should be lowered to increase affordability and patient access.

READ MORE

Research in Review

High-grade serous ovarian cancer can be categorized in five molecular subtypes associated with survival and surgical outcomes.

READ MORE

New research questions the value of risk-reducing mastectomy within five years of ovarian cancer diagnosis in patients with BRCA mutations.

READ MORE

A tool for measuring blood flow and volume to ovarian cancer tumors accurately predicts the effectiveness of treatment.

READ MORE

Women with advanced ovarian cancer who express a certain tumor antigen will likely experience a shorter progression-free survival and overall survival than those without the antigen.

READ MORE

Resources

The American College of Obstetricians and Gynecologists has recently updated its clinical guidelines for the management of hereditary breast and ovarian cancer syndrome.

READ MORE